After Buying Protana, Transition Therapeutics Drops Biomarker Unit, Keeps Optimol Tech | GenomeWeb

Since acquiring Protana in November 2005, Transition Therapeutics has been using the company's Optimol technology to identify small molecules that have affinities to selected protein targets, including targets related to hypertension, anemia, and Alzheimer's disease, according to a person familiar with the developments. Protana's proteomics-based biomarker discovery business, in the meantime, has been abandoned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.